Ziprasidone and cognition: the evolving story.

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Cognitive impairment, a central characteristic of schizophrenia, can profoundly limit patients' ability to acquire or maintain skills needed for adequate functioning. Thus, research on the efficacy of antipsychotic medications is increasingly focusing on the possible benefits of these agents on cognitive function. Although data are limited, it appears that atypical antipsychotics consistently improve cognitive function to a greater extent than do older, conventional agents. This review focuses on the atypical agent ziprasidone and its effects on cognitive function. The most recent data on the cognitive effects of ziprasidone come from a comparative trial with olanzapine (40-80 mg b.i.d. and 5-15 mg q.d., respectively) and from 3 studies in which patients were switched to ziprasidone (40-160 mg/day) because of suboptimal efficacy or tolerability with other antipsychotics. In general, ziprasidone-treated patients demonstrated significant improvements in multiple cognitive domains--such as episodic memory, attention/vigilance, executive function, and visuomotor speed--that are generally associated with improved functional outcome. In the switching studies, path analysis indicated that improvement on the Positive and Negative Syndrome Scale (PANSS) cognitive subscale directly affected changes on the PANSS anxiety-depression cluster and a PANSS "prosocial" subscale composed of items related to social engagement. Improvement in cognitive function observed with ziprasidone may have implications for long-term patient outcomes.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalThe Journal of clinical psychiatry
Volume64 Suppl 19
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Cognition
Antipsychotic Agents
olanzapine
Aptitude
Episodic Memory
Executive Function
Schizophrenia
Anxiety
ziprasidone
Depression
Research

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Ziprasidone and cognition : the evolving story. / Harvey, Philip D.

In: The Journal of clinical psychiatry, Vol. 64 Suppl 19, 01.12.2003, p. 33-39.

Research output: Contribution to journalArticle

@article{c8eeca7fcdf2415ca44ac828e8c7391e,
title = "Ziprasidone and cognition: the evolving story.",
abstract = "Cognitive impairment, a central characteristic of schizophrenia, can profoundly limit patients' ability to acquire or maintain skills needed for adequate functioning. Thus, research on the efficacy of antipsychotic medications is increasingly focusing on the possible benefits of these agents on cognitive function. Although data are limited, it appears that atypical antipsychotics consistently improve cognitive function to a greater extent than do older, conventional agents. This review focuses on the atypical agent ziprasidone and its effects on cognitive function. The most recent data on the cognitive effects of ziprasidone come from a comparative trial with olanzapine (40-80 mg b.i.d. and 5-15 mg q.d., respectively) and from 3 studies in which patients were switched to ziprasidone (40-160 mg/day) because of suboptimal efficacy or tolerability with other antipsychotics. In general, ziprasidone-treated patients demonstrated significant improvements in multiple cognitive domains--such as episodic memory, attention/vigilance, executive function, and visuomotor speed--that are generally associated with improved functional outcome. In the switching studies, path analysis indicated that improvement on the Positive and Negative Syndrome Scale (PANSS) cognitive subscale directly affected changes on the PANSS anxiety-depression cluster and a PANSS {"}prosocial{"} subscale composed of items related to social engagement. Improvement in cognitive function observed with ziprasidone may have implications for long-term patient outcomes.",
author = "Harvey, {Philip D}",
year = "2003",
month = "12",
day = "1",
language = "English",
volume = "64 Suppl 19",
pages = "33--39",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",

}

TY - JOUR

T1 - Ziprasidone and cognition

T2 - the evolving story.

AU - Harvey, Philip D

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Cognitive impairment, a central characteristic of schizophrenia, can profoundly limit patients' ability to acquire or maintain skills needed for adequate functioning. Thus, research on the efficacy of antipsychotic medications is increasingly focusing on the possible benefits of these agents on cognitive function. Although data are limited, it appears that atypical antipsychotics consistently improve cognitive function to a greater extent than do older, conventional agents. This review focuses on the atypical agent ziprasidone and its effects on cognitive function. The most recent data on the cognitive effects of ziprasidone come from a comparative trial with olanzapine (40-80 mg b.i.d. and 5-15 mg q.d., respectively) and from 3 studies in which patients were switched to ziprasidone (40-160 mg/day) because of suboptimal efficacy or tolerability with other antipsychotics. In general, ziprasidone-treated patients demonstrated significant improvements in multiple cognitive domains--such as episodic memory, attention/vigilance, executive function, and visuomotor speed--that are generally associated with improved functional outcome. In the switching studies, path analysis indicated that improvement on the Positive and Negative Syndrome Scale (PANSS) cognitive subscale directly affected changes on the PANSS anxiety-depression cluster and a PANSS "prosocial" subscale composed of items related to social engagement. Improvement in cognitive function observed with ziprasidone may have implications for long-term patient outcomes.

AB - Cognitive impairment, a central characteristic of schizophrenia, can profoundly limit patients' ability to acquire or maintain skills needed for adequate functioning. Thus, research on the efficacy of antipsychotic medications is increasingly focusing on the possible benefits of these agents on cognitive function. Although data are limited, it appears that atypical antipsychotics consistently improve cognitive function to a greater extent than do older, conventional agents. This review focuses on the atypical agent ziprasidone and its effects on cognitive function. The most recent data on the cognitive effects of ziprasidone come from a comparative trial with olanzapine (40-80 mg b.i.d. and 5-15 mg q.d., respectively) and from 3 studies in which patients were switched to ziprasidone (40-160 mg/day) because of suboptimal efficacy or tolerability with other antipsychotics. In general, ziprasidone-treated patients demonstrated significant improvements in multiple cognitive domains--such as episodic memory, attention/vigilance, executive function, and visuomotor speed--that are generally associated with improved functional outcome. In the switching studies, path analysis indicated that improvement on the Positive and Negative Syndrome Scale (PANSS) cognitive subscale directly affected changes on the PANSS anxiety-depression cluster and a PANSS "prosocial" subscale composed of items related to social engagement. Improvement in cognitive function observed with ziprasidone may have implications for long-term patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=1342264800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342264800&partnerID=8YFLogxK

M3 - Article

C2 - 14728088

AN - SCOPUS:1342264800

VL - 64 Suppl 19

SP - 33

EP - 39

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

ER -